Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Martin Donsbach"'
Autor:
Marija Pesic, Thomas Stöhr, Joachim Ossig, Keith Borkett, Martin Donsbach, Van-Anh Dao, Lynn Webster, Frank Schippers
Publikováno v:
Drugs in R&D, Vol 20, Iss 3, Pp 267-277 (2020)
Abstract Background and Objectives Remimazolam is a new ultra-short-acting benzodiazepine currently being developed for intravenous use in procedural sedation, general anaesthesia, and intensive care unit sedation. Benzodiazepines represent a drug cl
Externí odkaz:
https://doaj.org/article/1d7e4135fdc34fe2a7679e3bb117e9d9
Autor:
Lynn R. Webster, Thomas Stohr, Martin Donsbach, Frank Schippers, Keith Borkett, Joachim Ossig, Marija Pesic, Van-Anh Dao
Publikováno v:
Drugs in R&D, Vol 20, Iss 3, Pp 267-277 (2020)
Drugs in R&D
Drugs in R&D
Background and Objectives Remimazolam is a new ultra-short-acting benzodiazepine currently being developed for intravenous use in procedural sedation, general anaesthesia, and intensive care unit sedation. Benzodiazepines represent a drug class assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0207e8c27b0408874728bf10f48db05e
https://doaj.org/article/1d7e4135fdc34fe2a7679e3bb117e9d9
https://doaj.org/article/1d7e4135fdc34fe2a7679e3bb117e9d9
Publikováno v:
European Journal of Clinical Pharmacology
Purpose Remimazolam is a novel and ultra-short-acting sedative currently developed for intravenous use in procedural sedation, general anesthesia, and ICU sedation. However, intravenous administration is not always appropriate, depending on the patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f784b474e34736435ec02334ce0709d6
https://pubmed.ncbi.nlm.nih.gov/32886178
https://pubmed.ncbi.nlm.nih.gov/32886178